RT Journal Article
SR Electronic
T1 Intraperitoneal Infusion of Recombinant Plasminogen Activator Inhibitor Type 2 Induced Apoptosis in Implanted Human Colon Cancer and Inhibited its Growth and Liver Metastasis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 693
OP 698
VO 28
IS 2A
A1 DAIHACHIRO SUWA
A1 HIROYUKI KONNO
A1 TATSUO TANAKA
A1 TETSUMEI URANO
YR 2008
UL http://ar.iiarjournals.org/content/28/2A/693.abstract
AB Antitumor effects of plasminogen activator (PA) inhibitors (PAIs) were analyzed in a mouse model of human colon cancer xenografts. Either recombinant PA inhibitor-1 (rPAI-1) or inhibitor-2 (rPAI-2) was injected intraperitoneally to nude mice bearing human colon cancer xenografts for 6 weeks. Primary tumors in rPAI-2-treated group were smaller (0.45±0.13 g, n=16) than in the other two groups (control: 0.73±0.24 g, n=15; rPAI-1: 0.62±0.29 g, n=19). Primary tumors in the rPAI-2-treated group exhibited less mature ductal structures and were significantly smaller. The apoptotic index was higher in the rPAI-2-treated group (4.64±2.12%) than in the other groups (control: 1.94±0.82%; rPAI-1: 2.08±1.07%). Liver metastasis was less frequent in the rPAI-1(5/19) and rPAI-2-treated groups (1/16) than in the control group (14/15). PAI-2 more effectively suppressed tumor metastasis and progression, probably by inducing apoptosis; some different unknown mechanism may cause the difference in both antitumor effect and the histological findings. This may indicate the therapeutic potential of these PAIs in malignant patients.